Roivant Appoints Chief Development Officer and Announces Multiple Collaborations in Targeted Protein Degradation

Roivant Sciences, Inc.

Roivant Sciences, Inc.

Srini Ramanathan

Srini Ramanathan, Development Director at Roivant Sciences

Srini Ramanathan, Development Director at Roivant Sciences

  • Dr. Srini Ramanathan has over 20 years of drug development experience and joins Roivant from Horizon Therapeutics where he built scientific R&D capabilities and teams to advance the company’s preclinical and clinical portfolio.

  • In addition to internal pipeline programs, Roivant Proteovant Therapeutics and VantAI companies have formed external drug development partnerships with leading companies to further innovate protein degradation

  • Collaborations with Blueprint Medicines, Janssen and Boehringer Ingelheim Include Cumulative Contingent Milestone Payments of Over $1 Billion and Product Royalties

BASEL, Switzerland and LONDON and NEW YORK and BOSTON, May 02, 2022 (GLOBE NEWSWIRE) — Roivant Sciences (Nasdaq: ROIV) today announced that Srini Ramanathan, Ph.D. will join the company as Chief Development Officer . Dr. Ramanathan has over 20 years of expertise in drug development for a wide range of diseases. He joins Roivant from Horizon Therapeutics where he served as senior vice president of research and development sciences and site manager of the South San Francisco office. At Horizon, Dr. Ramanathan was responsible for building various scientific roles in discovery and development supporting pipeline expansion, regulatory submissions, and business development activities. Earlier in his career, he held leadership positions at AbbVie and Gilead Sciences. He has contributed to the worldwide approval of several drugs in virology, oncology and autoimmune diseases, and has published numerous articles in peer-reviewed journals.

“I am thrilled to join Roivant, one of the industry’s most innovative companies, and look forward to supporting the advancement of new medicines across multiple modalities and therapeutic areas,” said Dr. Ramanathan.

Roivant also announced that two of its subsidiaries, Proteovant Therapeutics and VantAI, have entered into several recently announced research collaboration agreements focused on the discovery and development of novel protein degraders and next-generation E3 ligase platforms:

  • Proteovant and Blueprint drugs have formed a strategic collaboration that brings together Proteovant’s targeted protein degrader discovery and development platform, including biology, chemistry and proteomics capabilities, and VantAI’s leading artificial intelligence technologies for generation and optimization of degraders with the precision medicine expertise of Blueprint Medicine to discover new targeted protein degraders. The companies will jointly research important targets and advance the development of up to two new protein-degrading therapies.

  • VantAI and Janssen Pharmaceuticala recently announced a multi-year collaboration in which the two companies will leverage VantAI’s geometric deep learning platform to generate protein-degrading drug candidates for two important therapeutic targets and collaborate on discovery and implementation of E3 ligase platforms bound to these targets.

  • VantAI and Boehringer Ingelheim recently announced a research collaboration focused on degrading traditionally “unrecoverable” targets. The collaboration initially focuses on a degrader program combined with proprietary E3 ligase platforms for these specific targets. Both organizations and their scientists will leverage VantAI’s geometric deep learning platform to computationally streamline the design of these novel molecules optimized for E3 ligase platforms.

“I am excited about the progress of our collaborations in targeted protein degradation and the work our teams are doing with these innovative partners,” said Matt Gline, CEO of Roivant. “Furthermore, I am delighted to welcome Dr. Ramanathan to our leadership team and look forward to his contributions to our development organization.”

About Roivant
Roivant’s mission is to improve the delivery of healthcare to patients by treating every inefficiency as an opportunity. Roivant develops transformative medicines faster by creatively building technologies and developing talent, leveraging the Roivant platform to launch “Vants”, agile and focused biopharmaceutical and health technology companies. For more information, please visit

Forward-looking statements
This press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act. of 1934, as amended (the “Exchange Act”), which are generally identified by the use of words such as “anticipate”, “believe”, “continue”, “could”, “estimate”, “will expect”, “intend”, “may”, “could”, “plan”, “possible”, “potential”, “predict”, “plan”, “should”, “would” and variations of such words or similar expressions. The words may identify forward-looking statements, but the absence of such words does not mean that a statement is not forward-looking. We intend that these forward-looking statements be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act.

Our forward-looking statements include, but are not limited to, statements regarding our or our management’s expectations, hopes, beliefs, intentions or strategies regarding the future, and statements that are not historical facts, including statements about the clinical and therapeutic potential of our product candidates, the availability and success of key results from our ongoing clinical trials, any commercial potential of our product candidates, and any pending or potential litigation, including, but not limited thereto, our expectations regarding the outcome of such litigation and the costs and expenses associated with such litigation. In addition, any statement that refers to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, is a forward-looking statement.

Although we believe that our plans, intentions, expectations and strategies as reflected or implied by these forward-looking statements are reasonable, we cannot guarantee that the plans, intentions, expectations or strategies will be achieved or achieved. In addition, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, the risks set forth in the section Risk factors from our filings with the United States Securities and Exchange Commission. In addition, we operate in a highly competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based on the current expectations and beliefs of our management as of the date of this press release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. . . Except as required by applicable law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Roivant Investor Relations

Paul Davis
Roivant Science

A photo accompanying this ad is available at

Leave a Reply

Your email address will not be published.